Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation
European EBIT Plummets By A Third, Further Supply Disruptions Anticipated
Executive Summary
Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.
You may also be interested in...
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
2022 Hires Reflect Global Challenges And Opportunities
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
Fresenius Delivers First US Biosimilar Approval
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.